专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20160081925A1 A PHARMACEUTICAL COMPOSITION CONTAINING BUDESONIDE AND FORMOTEROL 审中-公开
标题翻译：含有BUDESONIDE和FORMOTEROL的药物组合物
公开(公告)号：US20160081925A1
公开(公告)日：2016-03-24
申请号：US14783533
申请日：2014-04-09
申请人： ZAMBON S.P.A.
发明人： Giovanni Caponetti , Loretta Maggi , Marco Sardina , Franco Castegini , Gianluigi Faiella , Daniela Rebolini
IPC分类号： A61K9/00 , A61K31/167 , A61K9/16 , A61K31/58
CPC分类号： A61K9/0075 , A61K9/1617 , A61K9/1623 , A61K31/167 , A61K31/58 , A61K2300/00
摘要： The present invention relates to drug formulations in dry powder form for administration by inhalation and indicated for the treatment of obstructive airway syndromes such as asthma and chronic obstructive pulmonary disease (COPD). In particular, the invention relates to an inhalable pharmaceutical composition comprising a first powder consisting of budesonide, or one of its pharmaceutically allowable salts, in a quantity greater than 5% w/w of said first powder, leucine in a quantity in the range of 5 to 70% w/w of said first powder, and lactose in a quantity in the range of 20 to 90% w/w of said first powder; a second powder consisting of formoterol, or one of its pharmaceutically allowable salts, in a quantity greater than 1% w/w of said second powder, leucine in a quantity in the range of 5 to 70% w/w of said second powder, and lactose in a quantity in the range of 20 to 90% w/w of said second powder; and a third powder consisting of leucine in a quantity in the range of 5 to 70% w/w of said third powder, and lactose in a quantity in the range of 20 to 90% w/w of said third powder. Said composition has a fine particle fraction (FPF) greater than 60% and a delivered fraction (DF) greater than 90%.
摘要翻译：本发明涉及用于通过吸入施用并指示用于治疗阻塞性气道综合征如哮喘和慢性阻塞性肺病（COPD）的干粉形式的药物制剂。特别地，本发明涉及一种可吸入药物组合物，其包含由布地奈德或其药学上允许的盐之一组成的第一种粉末，其量大于所述第一种粉末的5％w / w，亮氨酸的量范围为 5〜70％w / w的所述第一粉末，所述第一粉末的量为20〜90％w / w的乳糖; 由福莫特罗或其药学上允许的盐之一组成的第二粉末，其量大于所述第二粉末的1％w / w，亮氨酸的量为所述第二种粉末的5-70％w / w，和所述第二粉末的20至90％w / w范围内的量的乳糖; 和由所述第三粉末的5-70％（w / w）范围内的亮氨酸组成的第三粉末和所述第三粉末的量为20-90％w / w的量的乳糖。所述组合物具有大于60％的细颗粒级分（FPF）和大于90％的传递级分（DF）。

2. 发明授权

US10226421B2 Pharmaceutical composition containing budesonide and formoterol 有权
公开(公告)号：US10226421B2
公开(公告)日：2019-03-12
申请号：US14783533
申请日：2014-04-09
申请人： Zambon S.P.A.
发明人： Giovanni Caponetti , Loretta Maggi , Marco Sardina , Franco Castegini , Gianluigi Faiella , Daniela Rebolini
IPC分类号： A61K9/00 , A61K9/16 , A61K31/167 , A61K31/58
摘要： The present invention relates to drug formulations in dry powder form for administration by inhalation and indicated for the treatment of obstructive airway syndromes such as asthma and chronic obstructive pulmonary disease (COPD). In particular, the invention relates to an inhalable pharmaceutical composition comprising a first powder consisting of budesonide, or one of its pharmaceutically allowable salts, in a quantity greater than 5% w/w of said first powder, leucine in a quantity in the range of 5 to 70% w/w of said first powder, and lactose in a quantity in the range of 20 to 90% w/w of said first powder; a second powder consisting of formoterol, or one of its pharmaceutically allowable salts, in a quantity greater than 1% w/w of said second powder, leucine in a quantity in the range of 5 to 70% w/w of said second powder, and lactose in a quantity in the range of 20 to 90% w/w of said second powder; and a third powder consisting of leucine in a quantity in the range of 5 to 70% w/w of said third powder, and lactose in a quantity in the range of 20 to 90% w/w of said third powder. Said composition has a fine particle fraction (FPF) greater than 60% and a delivered fraction (DF) greater than 90%.

3. 发明公开

US20240041762A1 INHALABLE POWDER COMPRISING VORICONAZOLE IN CRYSTALLINE FORM 审中-公开
公开(公告)号：US20240041762A1
公开(公告)日：2024-02-08
申请号：US18266313
申请日：2021-12-10
申请人： Zambon S.p.A.
发明人： Laura Zanellotti , Loretta Maggi , Gianluigi Faiella , Nadia Magi , Valentina Nicosia , Franco Castegini , Giovanni Caponetti
IPC分类号： A61K9/00 , A61K9/16 , A61K47/18 , A61K31/506
CPC分类号： A61K9/0075 , A61K9/1617 , A61K47/183 , A61K31/506
摘要： The present invention relates to a dry powder composition for inhalation use obtained by spray drying, comprising voriconazole, or a pharmaceutically active salt thereof, in substantially crystalline form, in an amount greater than 50% by weight with respect to the total amount of the powder. Said powder has a respirable fraction (FPF) greater than 50%, an X90 lower than 6 μm and an MMAD lower than 5 μm.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式